Evidence map›Paper›PMID 41922346›Full record

ArticleNature communications2026

Mitochondrial vulnerability underlies myocarditis from COVID-19 mRNA vaccine.

Go Mori, Masayoshi Yamamoto, Kaori Ishikawa, Hiroaki Tamashiro, Hayate Suzuki, Seiya Mizuno, Kazuto Nakada, Atsushi Kawaguchi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Go MoriGraduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, Japan.
Masayoshi YamamotoDepartment of Cardiology, Institute of Medicine, University of Tsukuba, Tsukuba, Japan.
Kaori IshikawaInstitute of Life and Environmental Sciences, University of Tsukuba, Tsukuba, Japan.ORCID 0000-0001-9895-5996
Hiroaki TamashiroGraduate School of Science and Technology, University of Tsukuba, Tsukuba, Japan.
Hayate SuzukiLaboratory Animal Resource Center in Transborder Medical Research Center, Institute of Medicine, University of Tsukuba, Tsukuba, Japan.
Seiya MizunoLaboratory Animal Resource Center in Transborder Medical Research Center, Institute of Medicine, University of Tsukuba, Tsukuba, Japan.ORCID 0000-0002-6740-5817
Kazuto NakadaInstitute of Life and Environmental Sciences, University of Tsukuba, Tsukuba, Japan.
Atsushi KawaguchiGraduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, Japan. ats-kawaguchi@md.tsukuba.ac.jp.ORCID 0000-0002-5485-1578

Funding

Japan Agency for Medical Research and Development (AMED) JP20fk0108076; JP24fk0108691; JP22fk0108638; JP20wm0325019; JP23wm0325062; JP22gm1610008Japan Agency for Medical Research and Development (AMED) JP22fk0108638MEXT | Japan Science and Technology Agency (JST) JPMJFR204MMEXT | Japan Science and Technology Agency (JST) JPMJPF2017MEXT | Japan Science and Technology Agency (JST) JPMJS2124Ministry of Education, Culture, Sports, Science and Technology (MEXT) 23K23801Ministry of Education, Culture, Sports, Science and Technology (MEXT) 23K24136; 25K22548Takeda Science Foundation 2505T00093
6 · The paper itself

Abstract

mRNA vaccines against SARS-CoV-2 have been widely adopted to combat the COVID-19 pandemic. However, myocarditis has emerged as a rare but severe adverse effect, predominantly affecting young males. Here, we show that mitochondrial vulnerability is associated with mRNA vaccine-associated myocarditis. In our case-control study, patients with postvaccination myocarditis exhibited mitochondrial abnormalities. To examine the impact of mitochondrial damage, mRNA vaccines were administered to Polg

Indexed as

COVID-19COVID-19 VaccinesMitochondriaMyocarditisAnimalsCase-Control StudiesDNA Polymerase gammaFemaleHumansMaleMicemRNA VaccinesMyocytes, CardiacReactive Oxygen SpeciesSARS-CoV-2COVID-19 VaccinesDNA Polymerase gammamRNA VaccinesReactive Oxygen Species

Identifiers

PMID41922346
PMCPMC13212923

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.